Introduction
============

Oral squamous cell carcinoma (OSCC) is the most common head and neck malignancy and the sixth most common tumour worldwide ([@B66]). Despite advances in therapies, the overall 5-year survival rate has remained unchanged during the past decades, mainly due to delayed diagnosis ([@B21]). OSCC is typically preceded by potentially malignant disorders (PMD), a group of clinically suspicious lesions. Although the majority of PMD do not progress to OSCC, distinguishing high-risk PMD from low-risk PMD is challenging for dental practitioners ([@B68]). Furthermore, patients treated for OSCC are at risk of developing recurrences and secondary primary tumours, due to field cancerization and/or incomplete surgery ([@B12]). Currently, conventional oral examination (COE), consisting in visual and tactile assessment of accessible oral structures, followed by tissue biopsy still constitutes the gold standard for diagnosis of PMD and OSCC. However, there are some limitations of this procedure, such as sampling bias that can lead to underdiagnosis or misdiagnosis, particularly in multifocal lesions ([@B68]).

The possibility of making an early diagnosis is crucial for reducing high mortality rate and morbidity of OSCC patients. In the last years, several light-based detection systems (LBDS), based on optical properties of biological tissues, have emerged with claims of enhancing oral mucosal examinations and facilitating the detection of PMD and OSCC.

Furthermore, the recent evolution of nanotechnology may provide new opportunities to detect PMD and OSCC at an early stage ([@B13]). Several preclinical studies showed the potential to enhance diagnostic accuracy of optical diagnostic technologies (e.g., Raman spectroscopy) or imaging techniques (e.g., Magnetic resonance imaging) ([@B10]). Among the latter techniques, reflectance confocal microscopy seems to improve the evaluation of oral lesions, by detecting backscattered light from illuminated tissue, producing high resolution tissue map. However, several technological limitations need to be resolved to validate diagnostic accuracy ([@B38]). LBDS showed several advantages compared to the aforementioned approaches, such as low cost and ease of use. For these reasons, it is fundamental to conduct studies to evaluate the efficacy of nanotechnology implementation in LBDS.

The aim of this article is to review the literature on LBDS currently on the market (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}), providing clinicians with a better understanding of their advantages and limits, and possible future applications of nanotechnologies.

###### 

Published studies on VELscope^®^ for clinical detection of oral lesions.

  Author and year   Patients   Type of lesion   Sens    Spec    PPV     NPV
  ----------------- ---------- ---------------- ------- ------- ------- -------
  [@B52]            20         OSCC             95%     --      100%    --
  [@B36]            44         PMD, OSCC        98%     100%    100%    86%
  [@B56]            65         OL               95.9%   96.2%   --      --
  [@B27]            60         OL               72%     50%     76%     46%
  [@B42]            156        OL               50%     38.9%   6.4%    90.3%
  [@B32]            78         PMD, OSCC        94%     16%     45%     77%
  [@B50]            175        PMD, OSCC        80.7%   97.5%   93.9%   91.3%
  [@B2]             126        PMD              84.1%   15.3%   37.8%   61.1%
  [@B60]            64         OSCC             100%    80.8%   54.5%   100%
  [@B39]            85         OL               92%     77%     --      --
  [@B41]            130        OL               66.7%   6.0%    4.1%    75%
  [@B19]            112        PMD              30%     63%     19%     75%
  [@B55]            123        PMD              100%    74%     16.7%   100%
  [@B22]            60         PMD              97.9%   33.3%   85.5%   80%
  [@B58]            71         OL               100%    74.1%   46.4%   100%
  [@B30]            130        OL               67%     62%     29.8%   89%
  [@B26]            60         OL               40%     80%     62.5%   66.7%
  [@B14]            20         PMD              --      --      --      --
  [@B4]             30         Screening        --      --      --      --
  [@B49]            20         OSCC             91%     100%    100%    58.3%
  [@B59]            41         OSCC             33.3%   88.6%   33.3%   88.6%
  [@B67]            62         PMD, OSCC        85.9%   26.7%   83.3%   30.8%
  [@B20]            200        OL               76%     66.3%   24.4%   95.1%
  [@B6]             90         OSCC             --      --      --      --
  [@B23]            140        PMD, OSCC        98.3%   77.6%   91.7%   93.8%
  [@B1]             21         PMD, OSCC        90%     15%     40%     71%
  [@B17]            11         PMD              --      --      --      --
  [@B7]             18         OL               94.4%   100%    100%    50%

OL, oral lesions; PMD, potentially malignant disorders; OSCC, oral squamous cell carcinoma; Sens, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value. Where possible, missing data were recalculated

.

###### 

Published studies on light-based detection systems other than VELscope^®^ for clinical detection of oral lesions.

  Author and year   Device        Patients   Type of lesion   Sens    Spec    PPV     NPV
  ----------------- ------------- ---------- ---------------- ------- ------- ------- -------
  [@B24]            ViziLite      150        PMD              --      --      --      --
  [@B54]            ViziLite      40         PMD, OSCC        100%    14.3%   80%     100%
  [@B15]            ViziLite      134        PMD              --      --      --      --
  [@B31]            ViziLite      501        OL               --      --      --      --
  [@B18]            ViziLite      55         OL               100%    0%      18.2%   --
  [@B48]            ViziLite      100        Screening        --      --      --      --
  [@B16]            ViziLite      84         PMD              100%    55%     37%     100%
  [@B42]            ViziLite      102        OL               0%      75.5%   0%      94.8%
  [@B3]             ViziLite      126        OL               87%     24%     15%     92%
  [@B44]            ViziLite      30         PMD              57.6%   37.5%   79.2%   17.6%
  [@B53]            ViziLite      30         PMD, OSCC        85%     100%    100%    76.9%
  [@B62]            ViziLite      44         PMD              59%     78%     --      --
  [@B63]            ViziLite      60         PMD, OSCC        95.5%   84.6%   91.3%   91.7%
  [@B29]            ViziLite      44         PMD              100%    30%     26%     100%
  [@B9]             ViziLite      100        PMD              84.8%   41.2%   58.3%   70%
  [@B61]            Identafi      88         PMD (white)      50%     98%     50%     98%
                                             (violet)         50%     81%     11%     97%
                                             (green)          0%      86%     0%      95%
  [@B35]            Identafi      124        PMD              82%     87%     --      --
  [@B43]            Identafi      21         OL               --      --      --      --
  [@B33]            Identafi      342        screening        --      --      --      --
  [@B34]            Identafi      88         OL (white)       100%    100%    100%    100%
                                             (Violet)         27.5%   96.3%   61.1%   86.4%
                                             (Green)          40%     71.7%   22.9%   85.1%
  [@B40]            Microlux/DL   50         PMD              77.8%   70.7%   36.8%   93.5%
  [@B25]            Microlux/DL   599        Screening        100%    32.4%   17.9%   100%
  [@B46]            GOCCLES       32         PMD, OSCC        100%    93%     92%     100%
  [@B45]            GOCCLES       61         PMD              96.9%   3.1%    50%     50%

OL, oral lesions; PMD, potentially malignant disorders; OSCC, oral squamous cell carcinoma; Sens, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value. Where possible, missing data were recalculated

.

ViziLite^®^
===========

ViziLite^®^ (Zila Pharmaceuticals, Phoenix, AZ, United States) is a chemiluminescence-based detection device designed to facilitate the early identification of PMD and OSCC. In 2002 ViziLite^®^ became the first device approved by FDA for this purpose ([@B48]). This is a disposable capsule formed by an outer shell of flexible plastic containing acetyl salicylic acid and an inner glass vial containing hydrogen peroxide. To activate it, the capsule is bent to break the inner glass vial, triggering the reaction of the chemicals contained in the two compartments. Consequently, a bluish-white light (430--580 nm) is produced, lasting for 10 min ([@B37]). A modified version (ViziLite^®^ PLUS) consists of a combination of chemiluminescence and toluidine blue (TB) marking system, an acidophilic dye that selectively stains acidic substances such as DNA. Furthermore, an accessory eyewear has been developed, to allow better isolation of chemiluminescent light ([@B57]). Its clinical use requires a 1-min rinse of 1% acetic acid solution, to desiccate oral tissues, followed by oral examination with 430--580 nm wavelength light. The altered epithelial cells, due to higher nuclear/cytoplasmic ratio, reflect the light and cause the appearance of an "aceto-white" lesion, whereas normal cells appear blue ([@B47]).

The first studies regarding ViziLite^®^, published in 2004--2007, were conducted on subjects with different clinical conditions, ranging from normal mucosa to diagnosed OSCC, with the aim to explore the diagnostic utility of chemiluminescence-based strategies (Table [2](#T2){ref-type="table"}). In the first reported study, ViziLite^®^ identified a subclinical lesion, suggesting its utility in identifying occult epithelial abnormalities ([@B24]). In a small cohort of patients with oral lesions, ViziLite^®^ appears to be a better diagnostic tool than TB in detection of OSCC and PMD ([@B54]). Another study highlights the ability of ViziLite^®^ to show brighter and better demarcated lesions than using incandescent light, aiming to enhance the identification of lesions that could be biopsied ([@B15]). Unfortunately, these results have not been confirmed, which failed to demonstrate significant improvement in identification and evaluation of oral lesions ([@B18]; [@B48]). Interestingly, a cross-sectional study compared ViziLite^®^ and VELscope^®^ to evaluate their clinical utility in diagnosing oral lesions, but the authors failed to demonstrate any superiority to COE ([@B42]).

For this reason, a new version of this device has been developed (ViziLite^®^ PLUS), aiming to improve the diagnostic power of TB marking system. First results were encouraging, showing that TB reduced the number of false positive cases leaving the false negative rate unchanged ([@B16]). On the contrary, ViziLite^®^ PLUS does not seems to be useful to detect malignancies in patients with clearly visible lesions ([@B44]). In fact, some authors described the better diagnostic accuracy of ViziLite^®^ with respect to TB staining alone ([@B53]; [@B63]), justifying the combined use of these two techniques.

Recently, the results of a clinical study suggested that, although the adjunct of TB to ViziLite^®^ reduced the false positive cases without increasing the number of false negatives, there are little benefits in using this device in general dental practise ([@B9]).

In conclusion, despite the fact that ViziLite^®^ facilitates the identification of hyperkeratotic areas and may increase the visibility of mucosal lesions, the main limitation is currently the high proportion of false positive and false negative tests, regarding the identification of dysplastic areas rather than hyperkeratosis ([@B11]).

Velscope^®^
===========

VELscope^®^ (LED Medical Diagnostics, White Rock, BC, Canada) is a hand-held non-magnifying device for direct visualisation of oral mucosa autofluorescence that became commercially available after FDA approval in 2006 ([@B4]). No need of technical measures, such as the use of dimmed light, pre-rinse or lesion-marking solutions, make VELscope^®^ easy to use. It uses a 120 W arc-lamp and a series of philtres and reflectors optimised for producing 400--460 nm wavelength light. The light emitted reaches oral mucosa and excites endogenous autofluorescence substances, called fluorophores ([@B67]). Preliminary studies, regarding small groups of patients, gave encouraging results (Table [1](#T1){ref-type="table"}). In the first reported study, 44 patients with confirmed oral dysplasia or OSCC were evaluated with both COE and VELscope^®^. The results showed that the device can differentiate PMD and OSCC from normal oral mucosa, with high sensitivity and specificity levels ([@B36]). These results were confirmed in a small OSCC cohort study, in which the use of autofluorescence-guided examination was able to identify subclinical high-risk fields with cancerous changes ([@B52]). In a study conducted on 60 patients using a semi-quantitative grading system for autofluorescence, VELscope^®^ demonstrate good sensitivity and a better ability to recognise high-grade lesions than COE ([@B27]). Another study evaluated 65 subjects with VELscope^®^, using a specific algorithm based on the ratio of red-to-green fluorescence. The authors found that 405 nm wavelength light was able to discriminate neoplastic and non-neoplastic tissue with high sensitivity and specificity ([@B56]).

In a cross-sectional study, 175 patients with at least one clinical lesion were evaluated using VELscope^®^. However, despite the good results, the authors warned that this device could lead to overdiagnosis if used by non-specialists ([@B50]). In fact, in the following years several studies on patients with PMD or OSCC reported low specificity values, highlighting this as the primary limitation of VELscope^®^ ([@B2]; [@B32]; [@B60]). For these reason, other authors concluded that VELscope^®^ examination alone does not provide significant diagnostic benefit beyond COE in screening for PMD and OSCC, also due to interobserver variability ([@B19]; [@B41]). These results were confirmed by a study on 200 patients, limiting the utility of autofluorescence for OSCC screening ([@B20]).

One effort to overcome these shortcomings consists of adding the VELscope^®^ exam to the COE. Indeed, as reported by several authors, the combination of COE and VELscope^®^ examination in patients with oral lesions could provide a significative diagnostic yield ([@B39]; [@B55]; [@B22]). However, these results must be interpreted carefully due to the different inclusion and exclusion criteria used to select the patient cohorts, which can influence both sensitivity and specificity.

Other studies focused on combining VELscope^®^ and other diagnostic tests, aiming to find out better approaches to improve detection of PMD and OSCC. For example, the combination approaches of tissue autofluorescence and salivary protoporphyrin IX levels seems to be effective to distinguish between normal mucosa and high-risk lesions ([@B30]). The use of quantitative analysis of autofluorescence were developed to solve the problem of interobserver variability. Novel methods such as quadratic discriminant analysis or luminance ratio were promising, showing a strong concordance with histopathological diagnosis ([@B23]; [@B67]). Recently, a retrospective study based on oral photograph was conducted to find colour distribution patterns related to neoplastic lesions. The fluorescence analysis showed differences in the red-to-green ratios of neoplastic areas, suggesting its clinical utility to detect early OSCC ([@B6]).

Recently, tissue autofluorescence was used to investigate biological aspects of oral carcinogenesis. In the first *in vitro* study, VELscope^®^ was used to investigate the autofluorescence in a rat tongue carcinogenesis model. The results showed significant changes in autofluorescence pattern during progression to dysplasia and carcinoma ([@B49]). In another study, RNA sequencing technique was used to identify molecular differences related to autofluorescence patterns. Results were encouraging, demonstrating that the autofluorescence-based excision was successful in achieving a clear molecular margin when excising PMD ([@B17]). These results confirmed those previously reported in literature, in which VELscope^®^ demonstrated that the actual sizes of some lesions are significantly larger than they look clinically ([@B14]).

In conclusion, several criticisms have been made about VELscope^®^, mainly focused to the limited capacity to extend the use of this device in general dental practise. Future research directions are aimed at improving the specificity of this device, allowing wider clinical use of VELscope^®^ in routine general practise ([@B5]).

Identafi^®^
===========

Identafi^®^ (StarDental - DentalEZ, Lancaster, PA, United States) is a probe-like device designed for multispectral screening of PMD, approved by FDA in 2009 as oral screening device ([@B64]). Identafi^®^ has three light sources of different wavelengths: white, violet (405 nm), and green-amber (545 nm) lights, that can be sequentially used in oral examination. While white light provides classical visualisation of oral mucosa, violet light excites endogen fluorophores, enabling the assessment of mucosa autofluorescence, like VELscope^®^. Green-amber light, through the reflectance spectroscopy, excites haemoglobin molecules in the blood, with the aim to visualise the vasculature ([@B43]). A mirror is attached to the probe to help visualise relatively obscure areas in oral cavity.

The first clinical trial with Identafi^®^ was conducted on 88 patients who were treated previously for OSCC (Table [2](#T2){ref-type="table"}). Screening results with white, violet, and green lights were compared to each other, showing limited benefits of tissue reflectance and autofluorescence in detecting high-risk lesions ([@B61]). In 2012, was reported a case series of PMD patients with the aim to evaluate the efficacy of Identafi^®^. Although the results are not clearly described, this device seems to be helpful in identifying characteristics not otherwise visible to the COE ([@B35]).

In a pilot study, Identafi^®^ was used to evaluate tissue vascularity of PMD and to compare with the histological grading of the lesions using a vascular marker (CD34). The results found a correlation between tissue reflectance and histological assessment of vascular structure, in both OSCC and non-cancerous lesions ([@B43]).

Two studies on the effectiveness of Identafi^®^ were conducted on Australian population. In the first one, 342 urban Indigenous community members were screened for oral lesions using reflectance spectroscopy and autofluorescence imaging. Identafi^®^ improved the visibility of oral cavity lesions and was capable to find new lesions not seen during COE, although the prevalence of oral pigmentation in this community could hamper the use of autofluorescence screening systems ([@B33]). In the second study, 88 patients were evaluated with Identafi^®^, showing good specificity, negative predictive value, and accuracy ([@B34]).

Taken together, the use of Identafi provide the clinician with more data than COE. Unfortunately, the results interpretation requires high level of experience and clinical training in oral pathology, suggesting that its usage should be limited to reference centres for oral pathology ([@B34]).

Other Devices
=============

Microlux/DL^TM^ (AdDent Inc., Danbury, CT, United States) is a chemiluminescence-based device which became commercially available after FDA approval in 2005. This device has a diffused blue-white LED light source and a fibre optic light guide ([@B40]). It uses the same principles of ViziLite^®^: after 1-min rinse with 1% acetic acid, oral examination is performed with 460--555 nm wavelength light. Altered epithelial cells cause the appearance of "aceto-white" lesions, and LED light source makes the lesion more easily recognisable. Furthermore, the use of TB can be used in conjunction with Microlux/DL^TM^, to enhance the visualisation of dysplastic areas ([@B25]). In 2009 was conducted a study on 50 patients with oral white lesions to evaluate the efficacy of Microlux/DL^TM^. The results showed that this device can enhance visualisation of oral mucosa, but no clinical improvement was observed, due to poor ability to distinguish between benign and malignant lesions ([@B40]). Another trial that evaluated the effectiveness of Microlux/DL^TM^ was carried out in 2014. 599 patients were examined with COE and Microlux/DL^TM^ with and without TB, showing high sensitivity but low specificity, indicating that this device is not effective to distinguish between benign and malignant lesions, although seems to be a promising screening test for oral lesions ([@B25]).

GOCCLES^®^ is a medical device (Pierrel S.p.A, Italy) approved by FDA in 2015. This is a low cost and easy-to-use device consisting in a pair of glasses equipped with special optical philtres that allows autofluorescence detection. Indeed, GOCCLES^®^ was created to provide an easy and low cost mean of identification of autofluorescence abnormalities in oral cavity with the use of any dental curing light ([@B45]). In 2010 was reported the first study on GOCCLES^®^ in a small cohort of selected patients, showing high sensitivity and specificity ([@B46]). Five years later, a non-randomised multicentre trial was conducted on patients at risk for OSCC, suggesting the need for further researches to define the diagnostic performance of this device ([@B45]). Indeed, despite the low cost of GOCCLES^®^ could encourage more careful examinations, its main limitation seems to be the interobserver variability, that could be overcome by proper training.

In recent years, other instruments have been developed and commercialised for facilitate the early identification of oral lesions. Their operating principle is equivalent to the devices described above, using either autofluorescence or chemiluminescence detection. However, their clinical effectiveness is currently hampered by the lack of published studies. For these reasons, they will only be mentioned briefly here. Bio/Screen^®^ (AdDent Inc., Danbury, CT, United States), an instrument with five violet (390--430 nm) high-power LED, designed to enhance the visualisation of mucosal abnormalities through the use of tissue autofluorescence ([@B28]).

Orascoptic DK^TM^ system (Orascoptic, Middleton, WI, United States) is another chemiluminescence-based device, designed to improve the visualisation of oral lesions through the use of blue-white LED light and oral rinse of 1% acetic acid solution ([@B51]).

Sapphire^®^ Plus LD (DenMat Holdings, Lompoc, CA, United States), DentLight DOE^TM^ Oral Exam System (DentLight, Richardson, TX, United States), and OralID^TM^ 2.0 (Forward Science Technologies, Stafford, TX, United States) are other tissue autofluorescence-based devices developed in order to detect oral lesions ([@B28]).

Conclusion and Future Perspectives
==================================

The diagnostic techniques presented here showed great potential for screening and monitoring oral lesions ([@B37]). Unfortunately, to date several factors hinder an extensive use of these devices: (1) data do not demonstrate clear superiority of these methods compared to COE; (2) there remains the need for well-designed multicentre prospective studies; (3) these devices exhibit a not-negligible interobserver variability, limiting their use to clinicians with significant experience in oral pathology ([@B51]; [@B8]).

However, the current evidence suggests that these devices: (1) seem to be useful in assessing lesion margins that must be biopsied and, therefore, may be useful in surgical management; (2) can be used to investigate biological aspects of oral carcinogenesis, leading to more accurate methods for interpreting data from LBDS; (3) can be enhanced with new approaches used to analyse optical imaging data, with the aim to quantify the results obtained; (4) lowering the costs of these devices could indirectly lead to greater attention for oral lesions among both patients and general dental practitioners, allowing in turn to promote a culture of oral cancer prevention ([@B8]; [@B45]); (5) finally, the possibility of implementing LBDS through the use of tissue-marking dyes can in principle allows to develop strategies for the use of nanoparticles. Indeed, nanoparticles can provide molecular targeted imaging, with higher image contrast and resolution. For example, a promising nanotechnology in oral diagnostic research is the quantum dots, consisting in nanometre-sized semiconductor crystals ([@B65]). The biophysical characteristics of these particles confer several advantages over conventional dyes and fluorescent proteins. The possibility to link the quantum dots to molecules with the ability to target cancer cells make them ideal for diagnostic applications in detecting PMD and OSCC ([@B10]). Therefore, the use of nanotechnologies could be the next step in the evolution of LBDS, providing devices that can help clinicians to detect and better monitor oral lesions.
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